Clinical trial NCT06058910: Bilistick Point-of-care System 2.0 Bilirubin Validation
Official title: Bilistick Point-of-care System 2.0 Bilirubin Validation Utilizing Blood Samples Collected in Pediatric Patients
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Neonatal Screening
Kernicterus
Newborn Jaundice
Point-of-Care Testing
Lead sponsor: Kettering Health Network
Sponsor class: OTHER
Collaborators: name: Bilimetrix s.r.l.
First posted: 2023-09-28
Enrollment: 80
Sex: ALL
Maximum age (years): 2
Standard ages: CHILD
Accepts healthy volunteers: yes
Observational model: OTHER
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: This study will include newborn pediatric patients under 2-weeks of age who are necessary to conduct this study and are representative of the target population for use with this device.

Brief summary: This is a validation study involving the Bilistick System 2.0 point-of-care bilirubin measuring device. The validation will be conducted by comparing bilirubin measurements utilizing the standard-of-care blood sample collected for both a diagnostic reference device and Bilistick System 2.0 point-of-care device. Whole blood samples collected from male or female newborns (\<2-weeks of age) born at a Kettering Health Network facility to obtain a total of 80 valid comparison pairs between the reference device and the Bilistick System 2.0 point-of-care device with current laboratory standards.

Detailed description: The investigators propose a prospective diagnostic validation study comparing total bilirubin values measured under the reference clinical methodology to the point-of-care Bilistick System 2.0 testing device. During the routine standard-of-care whole blood sample collection (0.5 milliliters whole blood draw) for bilirubin assessments under reference clinical methodology, an additional 0.035 milliliters of whole blood will be collected (not to exceed more than 2 sample collections per week) for measurement in the point-of-care Bilistick System 2.0. The resulting Bilistick System 2.0 data will be recorded, but will not be entered in the patients' electronic medical records or used for any diagnostic or medical decision purposes.

Whole blood samples collected from male or female newborns (\<2-weeks of age) born at a Kettering Health Network facility to obtain a total of 80 valid comparison pairs between the reference device and the Bilistick System 2.0 point-of-care device will be included on study.

Consent forms will be Institutional Review Board (IRB)-approved and the parent or legal guardian of the participant will be asked to read the document. The investigator or delegated study staff will explain the research study to the parent or legal guardian of the participant and answer any questions that may arise. A verbal explanation will be provided to allow for the comprehension of the purposes, procedures, and potential risks of the study and rights of the research participant. The parent or legal guardian of the participant will be informed that participation is voluntary, they can withdraw at any time. Sufficient opportunity will be provided to carefully review the written consent form and ask questions prior to signing. The parent or legal guardian of the participant will sign the informed consent document prior to any procedures being done specifically for the study.

Since this study uses blood collected during an existing standard of care blood collection (i.e., there will be NO separate research-specific heel stick) this study poses no additional risk and parental permission will be required by only one parent.

Eligibility criteria: Inclusion Criteria:

* Participant is \<2-weeks of age
* Participant is inpatient hospital status
* Participant undergoing routine blood sample collection for total serum bilirubin

Exclusion Criteria:

* Parent or legal guardian of participant is Non-English speaking or reading
* Parent or legal guardian of participant unable to give informed consent/parental permission

Primary outcomes:
measure: Bilistick Total Bilirubin
timeFrame: birth through 2-weeks of age
measure: Reference Clinical Total Bilirubin
timeFrame: birth through 2-weeks of age
Secondary outcomes:
Other outcomes:
Locations:
city: Kettering
country: United States
facility: Kettering Health Main Campus
state: Ohio
Study officials:
affiliation: Kettering Health
name: Jonathan D Toot, MD
role: PRINCIPAL_INVESTIGATOR
References: